ID: ALA175630

Max Phase: Preclinical

Molecular Formula: C15H13NO6

Molecular Weight: 303.27

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C(O)c1cccc(NC(=O)C2C(C(=O)O)[C@@H]3C=C[C@H]2O3)c1

Standard InChI:  InChI=1S/C15H13NO6/c17-13(16-8-3-1-2-7(6-8)14(18)19)11-9-4-5-10(22-9)12(11)15(20)21/h1-6,9-12H,(H,16,17)(H,18,19)(H,20,21)/t9-,10+,11?,12?/m1/s1

Standard InChI Key:  GHYJXCXAMYPBLP-QKEWWQLBSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 303.27

Molecular Weight (Monoisotopic): 303.0743

AlogP: 0.98

#Rotatable Bonds: 4

Polar Surface Area: 112.93

Molecular Species: ACID

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 3.39

CX Basic pKa:

CX LogP: 0.85

CX LogD: -5.71

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.71

Np Likeness Score: -0.53

References

1. Hart ME, Chamberlin AR, Walkom C, Sakoff JA, McCluskey A..  (2004)  Modified norcantharidins; synthesis, protein phosphatases 1 and 2A inhibition, and anticancer activity.,  14  (8): [PMID:15050639] [10.1016/j.bmcl.2004.01.093]

Source

Source(1):

• Scientific Literature